Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Canton Biologics Raises $41 Million in C Round for Biologic CDMO Services

publication date: Sep 18, 2023

Guangzhou Canton Biologics closed a $41 million Series C financing round to expand its biologic CDMO services. Founded in 2016, Canton is an international company founded by a group of Chinese returnees at Guangzhou international Biological Island. It offers end-to-end services ranging from biopharma CMC development to commercial production and global clinical supply. The company claims to offer outstanding results in high-yield cell line development, complex protein expression and manufacturing for international markets. The C round was led by SDIC Venture Capital. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital